{"pmcid": "PMC5508045", "pmid": "28550460", "variant": "rs9923231", "sentences": ["Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC."]}
{"pmcid": "PMC5508045", "pmid": "28550460", "variant": "rs1057910", "sentences": ["Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA."]}
{"pmcid": "PMC5508045", "pmid": "28550460", "variant": "rs2108622", "sentences": ["Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC."]}
{"pmcid": "PMC5508045", "pmid": "28550460", "variant": "rs887829", "sentences": ["Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T."]}
{"pmcid": "PMC4916189", "pmid": "26715213", "variant": "CYP2B6*1", "sentences": ["CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1."]}
{"pmcid": "PMC4916189", "pmid": "26715213", "variant": "CYP2B6*9", "sentences": ["CYP2B6 *9 is associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV as compared to CYP2B6 *1/*1."]}
{"pmcid": "PMC4916189", "pmid": "26715213", "variant": "rs3745274", "sentences": ["Genotypes GT + TT are associated with increased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotype GG.", "Allele T is not associated with virological response when treated with efavirenz in people with HIV Infections as compared to allele G."]}
{"pmcid": "PMC4916189", "pmid": "26715213", "variant": "rs2472677", "sentences": ["Genotype TT is associated with decreased likelihood of discontinuation when treated with efavirenz in people with HIV Infections as compared to genotypes CC + CT."]}
{"pmcid": "PMC4916189", "pmid": "26715213", "variant": "rs1045642", "sentences": ["Genotype AA are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype GG."]}
{"pmcid": "PMC4916189", "pmid": "26715213", "variant": "rs28399499", "sentences": ["Genotypes CC + CT are associated with decreased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype TT."]}
{"pmcid": "PMC4916189", "pmid": "26715213", "variant": "rs4803419", "sentences": ["Genotypes CT + TT are associated with increased risk of Central Nervous System Diseases when treated with efavirenz in people with HIV Infections as compared to genotype CC."]}
{"pmcid": "PMC12036300", "pmid": "40295977", "variant": "CYP2C19*1", "sentences": ["CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.", "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1."]}
{"pmcid": "PMC12036300", "pmid": "40295977", "variant": "CYP2C19*2", "sentences": ["CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.", "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1."]}
{"pmcid": "PMC12036300", "pmid": "40295977", "variant": "CYP2C19*17", "sentences": ["CYP2C19 *1/*2 + *2/*2 + *2/*17 is not associated with increased likelihood of Major Adverse Cardiac Events (MACE) when treated with clopidogrel as compared to CYP2C19 *1/*1.", "CYP2C19 *1/*17 + *17/*17 + *2/*17 is not associated with increased likelihood of Hemorrhage when treated with clopidogrel as compared to CYP2C19 *1/*1."]}
{"pmcid": "PMC554812", "pmid": "15743917", "variant": "HLA-B*58:01", "sentences": ["HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."]}
{"pmcid": "PMC554812", "pmid": "15743917", "variant": "HLA-DRB1*03:01", "sentences": ["HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."]}
{"pmcid": "PMC554812", "pmid": "15743917", "variant": "HLA-C*03:02", "sentences": ["HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."]}
{"pmcid": "PMC554812", "pmid": "15743917", "variant": "HLA-A*33:03", "sentences": ["HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."]}
{"pmcid": "PMC554812", "pmid": "15743917", "variant": "rs1594", "sentences": ["Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*67:01", "sentences": ["HLA-B *67:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*78:01", "sentences": ["HLA-B *78:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*51:02", "sentences": ["HLA-B *51:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*56:06", "sentences": ["HLA-B *56:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*39:01", "sentences": ["HLA-B *39:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-C*05:09", "sentences": ["HLA-C *05:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*15:32", "sentences": ["HLA-B *15:32 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-C*05:01", "sentences": ["HLA-C *05:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*51:01", "sentences": ["HLA-B *51:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*15:35", "sentences": ["HLA-B *15:35 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*15:12", "sentences": ["HLA-B *15:12 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-DRB1*08:01", "sentences": ["HLA-DRB1 *08:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*39:10", "sentences": ["HLA-B *39:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*38:02", "sentences": ["HLA-B *38:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*38:01", "sentences": ["HLA-B *38:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-DRB1*04:04", "sentences": ["HLA-DRB1 *04:04 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*56:01", "sentences": ["HLA-B *56:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*35:05", "sentences": ["HLA-B *35:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-DRB1*01:02", "sentences": ["HLA-DRB1 *01:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*39:09", "sentences": ["HLA-B *39:09 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*15:01", "sentences": ["HLA-B *15:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*15:27", "sentences": ["HLA-B *15:27 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*35:10", "sentences": ["HLA-B *35:10 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-C*04:06", "sentences": ["HLA-C *04:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*57:01", "sentences": ["HLA-B *57:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-C*04:07", "sentences": ["HLA-C *04:07 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*55:02", "sentences": ["HLA-B *55:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-DRB1*01:03", "sentences": ["HLA-DRB1 *01:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*55:01", "sentences": ["HLA-B *55:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*13:02", "sentences": ["HLA-B *13:02 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*15:25", "sentences": ["HLA-B *15:25 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*39:06", "sentences": ["HLA-B *39:06 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-C*04:03", "sentences": ["HLA-C *04:03 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*54:01", "sentences": ["HLA-B *54:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-DRB1*01:01", "sentences": ["HLA-DRB1 *01:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*52:01", "sentences": ["HLA-B *52:01 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Severe Cutaneous Adverse Reactions or Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-DRB1*10:01", "sentences": ["HLA-DRB1 *10:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-C*04:01", "sentences": ["HLA-C *04:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*39:05", "sentences": ["HLA-B *39:05 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-C*18:01", "sentences": ["HLA-C *18:01 is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "HLA-B*15:24", "sentences": ["HLA-B *15:24 is associated with decreased risk of Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms or Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "rs28399499", "sentences": ["Allele C is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome, Drug Reaction with Eosinophilia and Systemic Symptoms and Severe Cutaneous Adverse Reactions when treated with nevirapine in people with HIV Infections as compared to allele T."]}
{"pmcid": "PMC5561238", "pmid": "28819312", "variant": "rs3745274", "sentences": ["Allele T is associated with Epidermal Necrolysis, Toxic, Stevens-Johnson Syndrome and Drug Reaction with Eosinophilia and Systemic Symptoms when treated with nevirapine in people with HIV Infections as compared to allele G."]}
{"pmcid": "PMC10946077", "pmid": "38497131", "variant": "UGT1A1*1", "sentences": ["UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "UGT1A1 *28 is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1."]}
{"pmcid": "PMC10946077", "pmid": "38497131", "variant": "UGT1A1*6", "sentences": ["UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "UGT1A1 *6 is associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1."]}
{"pmcid": "PMC10946077", "pmid": "38497131", "variant": "UGT1A1*28", "sentences": ["UGT1A1 *6 + *28 is not associated with decreased likelihood of overall survival or progression-free survival when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1.", "UGT1A1 *28 is not associated with increased severity of Neutropenia, Leukopenia or Diarrhea when treated with irinotecan in people with Stomach Neoplasms as compared to UGT1A1 *1."]}
{"pmcid": "PMC6465603", "pmid": "31024313", "variant": "rs1142345", "sentences": ["Allele C is not associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to allele T."]}
{"pmcid": "PMC6465603", "pmid": "31024313", "variant": "rs116855232", "sentences": ["Genotypes CT + TT is associated with increased likelihood of Leukopenia when treated with azathioprine in people with Hepatitis, Autoimmune as compared to genotype CC."]}
{"pmcid": "PMC12038368", "pmid": "40297930", "variant": "rs4149056", "sentences": ["Genotypes CC + CT is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype TT."]}
{"pmcid": "PMC12038368", "pmid": "40297930", "variant": "rs2306283", "sentences": ["Genotypes AG + GG is associated with increased concentrations of simvastatin acid in people with Cardiovascular Disease or Dyslipidaemia as compared to genotype AA."]}
{"pmcid": "PMC10880264", "pmid": "38377518", "variant": "CYP2C19 intermediate metabolizer", "sentences": ["CYP2C19 intermediate metabolizer is associated with increased dose-adjusted trough concentrations of escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer.", "CYP2C19 intermediate metabolizer is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2C19 normal metabolizer."]}
{"pmcid": "PMC10880264", "pmid": "38377518", "variant": "CYP2D6 poor metabolizer", "sentences": ["CYP2D6 poor metabolizer is associated with increased likelihood of Psychomotor Agitation, Hyperkinesis or Impulse control disorder, unspecified when treated with escitalopram in children with Depression or Anxiety Disorders as compared to CYP2D6 normal metabolizer."]}
{"pmcid": "PMC10880264", "pmid": "38377518", "variant": "rs6311", "sentences": ["Genotypes CT + TT (assigned as intermediate metabolizer phenotype) is associated with increased likelihood of suicidal ideation, adverse events or deliberate self-harm when treated with escitalopram in children with Depression or Anxiety Disorders as compared to genotype CC (assigned as normal metabolizer phenotype) ."]}
{"pmcid": "PMC12331468", "pmid": "40786508", "variant": "rs1801265", "sentences": ["Genotypes AG + GG is associated with increased likelihood of Peripheral Nervous System Diseases when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotype AA."]}
{"pmcid": "PMC12331468", "pmid": "40786508", "variant": "rs1695", "sentences": ["Genotype GG is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG.", "Genotype GG is associated with increased likelihood of Mucositis when treated with FOLFOX or XELOX in people with Colorectal Neoplasms as compared to genotypes AA + AG."]}
{"pmcid": "PMC12331468", "pmid": "40786508", "variant": "rs11280056", "sentences": ["Genotypes TTA/TTA + TTA/TTAAAGTTA is associated with decreased likelihood of Peripheral Nervous System Diseases or Myelosuppression when treated with FOLFOX or XELOX in people with Colorectal Neoplasms."]}
{"pmcid": "PMC12331468", "pmid": "40786508", "variant": "rs45445694", "sentences": ["Genotype (GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3 is associated with increased likelihood of Hand-foot syndrome, Exanthema or Drug Toxicity when treated with FOLFOX or XELOX in people with Colorectal Neoplasms."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*1", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*1xN", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*2", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*2xN", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*3", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*4", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*4xN", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*5", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*6", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*9", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*10", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*17", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*29", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*35", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC6435416", "pmid": "30661084", "variant": "CYP2D6*41", "sentences": ["CYP2D6 *4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17 (assigned as intermediate metabolizer and poor metabolizer phenotype) are associated with increased likelihood of adverse events due to risperidone in children as compared to CYP2D6 *1/ *2xN + *1/*1xN + *1xN/ *2 + *1/ *2 + *1/*4 + *2/*4 + *1/*41 + *1/*35 + *2/*41 + *1/*9 + *1/*17 + *1/*5 + *3/*35 + *2/*5 + *2/*35 + *2/*17 + *35/*41 + *2/*6 + *1/*29 + *2/*2 + *1/*3 + *1/*1 (assigned as normal metabolizer and ultrarapid metabolizer phenotype) ."]}
{"pmcid": "PMC12319246", "pmid": "40761554", "variant": "rs2740574", "sentences": ["Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT."]}
{"pmcid": "PMC12319246", "pmid": "40761554", "variant": "rs3745274", "sentences": ["Genotype GT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation."]}
{"pmcid": "PMC12319246", "pmid": "40761554", "variant": "rs2306283", "sentences": ["Genotypes AA + AG is associated with decreased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation."]}
{"pmcid": "PMC12319246", "pmid": "40761554", "variant": "rs9282564", "sentences": ["Genotype TT is associated with decreased risk of Death when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes CC + CT."]}
{"pmcid": "PMC12319246", "pmid": "40761554", "variant": "rs2273697", "sentences": ["Genotype GG is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotypes AA + AG."]}
{"pmcid": "PMC12319246", "pmid": "40761554", "variant": "rs776746", "sentences": ["Genotype CC is associated with increased likelihood of overall survival when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CT."]}
{"pmcid": "PMC12319246", "pmid": "40761554", "variant": "rs4149056", "sentences": ["Genotype TT is associated with decreased likelihood of Transplant rejection when treated with tacrolimus in people with Kidney Transplantation."]}
{"pmcid": "PMC12319246", "pmid": "40761554", "variant": "rs4244285", "sentences": ["Genotype AA is associated with increased likelihood of Nephrotoxicity when treated with tacrolimus in people with Kidney Transplantation."]}
{"pmcid": "PMC3548984", "pmid": "23213055", "variant": "CYP2D6*1", "sentences": ["CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1."]}
{"pmcid": "PMC3548984", "pmid": "23213055", "variant": "CYP2D6*3", "sentences": ["CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1."]}
{"pmcid": "PMC3548984", "pmid": "23213055", "variant": "CYP2D6*4", "sentences": ["CYP2D6 *3/*3 + *4/*4 are associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1.", "CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1."]}
{"pmcid": "PMC3548984", "pmid": "23213055", "variant": "CYP2D6*6", "sentences": ["CYP2D6 *1/*3 + *1/*4 + *1/*6 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1."]}
{"pmcid": "PMC3548984", "pmid": "23213055", "variant": "CYP2D6*10", "sentences": ["CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1."]}
{"pmcid": "PMC3548984", "pmid": "23213055", "variant": "CYP2D6*41", "sentences": ["CYP2D6 *1/*10 + *1/*41 + *10/*10 + *41/*41 are not associated with increased likelihood of Recurrence when treated with tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1."]}
{"pmcid": "PMC10275785", "pmid": "37332933", "variant": "rs2043211", "sentences": ["Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AT."]}
{"pmcid": "PMC10275785", "pmid": "37332933", "variant": "rs4612666", "sentences": ["Genotype TT is associated with decreased response to etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes CC + CT."]}
{"pmcid": "PMC11971672", "pmid": "40184070", "variant": "CYP2C19*1", "sentences": ["CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) ."]}
{"pmcid": "PMC11971672", "pmid": "40184070", "variant": "CYP2C19*2", "sentences": ["CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) ."]}
{"pmcid": "PMC11971672", "pmid": "40184070", "variant": "CYP2C19*3", "sentences": ["CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) ."]}
{"pmcid": "PMC11971672", "pmid": "40184070", "variant": "CYP2C19*17", "sentences": ["CYP2C19 *1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3 (assigned as intermediate metabolizer and poor metabolizer phenotype) is associated with increased likelihood of Stroke, Myocardial Infarction or Death when treated with clopidogrel in people with Stroke as compared to CYP2C19 *1/*1 + *1/*17 + *17/*17 (assigned as normal metabolizer phenotype) ."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*1", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1.", "CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*2", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*3", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*4", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*5", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*9", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*14", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*15", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*16", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*17", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*19", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*24", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*28", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*29", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*31", "sentences": ["CYP3A4 *2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31 is associated with decreased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*11", "sentences": ["CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*18", "sentences": ["CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC11430164", "pmid": "39346054", "variant": "CYP3A4*33", "sentences": ["CYP3A4 *11 + *18 + *33 is associated with increased clearance of ticagrelor as compared to CYP3A4 *1."]}
{"pmcid": "PMC8790808", "pmid": "33768542", "variant": "HLA-DQA1*02:01", "sentences": ["HLA-DQA1 *02:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase."]}
{"pmcid": "PMC8790808", "pmid": "33768542", "variant": "HLA-DQB1*02:02", "sentences": ["HLA-DQB1 *02:02 is associated with increased risk of Hypersensitivity when treated with pegaspargase."]}
{"pmcid": "PMC8790808", "pmid": "33768542", "variant": "HLA-DRB1*07:01", "sentences": ["HLA-DRB1 *07:01 is associated with increased risk of Hypersensitivity when treated with pegaspargase."]}
{"pmcid": "PMC8790808", "pmid": "33768542", "variant": "rs9958628", "sentences": ["Allele T is associated with increased risk of Hypersensitivity when treated with pegaspargase as compared to allele A."]}
{"pmcid": "PMC11062152", "pmid": "38707740", "variant": "UGT1A1*1", "sentences": ["UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1."]}
{"pmcid": "PMC11062152", "pmid": "38707740", "variant": "UGT1A1*6", "sentences": ["UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1."]}
{"pmcid": "PMC11062152", "pmid": "38707740", "variant": "UGT1A1*28", "sentences": ["UGT1A1 *6 + *28 is not associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1.", "UGT1A1 *6/*6 + *28/*28 + *6/*28 is associated with increased risk of Neutropenia or Leukopenia when treated with fluorouracil, irinotecan and leucovorin in people with Pancreatic Neoplasms and Neoplasm Metastasis as compared to UGT1A1 *1/*1."]}
{"pmcid": "PMC3839910", "pmid": "23588310", "variant": "HLA-B*15:02", "sentences": ["HLA-B *15:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "HLA-B *15:02 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "HLA-B *15:02 is not associated with increased risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children."]}
{"pmcid": "PMC3839910", "pmid": "23588310", "variant": "HLA-A*31:01", "sentences": ["HLA-A *31:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.", "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.", "HLA-A *31:01 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children."]}
{"pmcid": "PMC3113609", "pmid": "21428769", "variant": "HLA-A*31:01", "sentences": ["HLA-A *31:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.", "HLA-A *31:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.", "HLA-A *31:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine."]}
{"pmcid": "PMC10786722", "pmid": "38216550", "variant": "rs56038477", "sentences": ["Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC."]}
{"pmcid": "PMC10786722", "pmid": "38216550", "variant": "rs1801160", "sentences": ["Genotypes CT + TT is associated with decreased activity of DPYD as compared to genotype CC."]}
{"pmcid": "PMC10786722", "pmid": "38216550", "variant": "rs2297595", "sentences": ["Genotypes CC + CT is associated with decreased activity of DPYD as compared to genotype TT."]}
{"pmcid": "PMC384715", "pmid": "15024131", "variant": "HLA-B*57:01", "sentences": ["HLA-B *57:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV Infections."]}
{"pmcid": "PMC3584248", "pmid": "23476897", "variant": "CYP2D6*1", "sentences": ["CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2."]}
{"pmcid": "PMC3584248", "pmid": "23476897", "variant": "CYP2D6*2", "sentences": ["CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2."]}
{"pmcid": "PMC3584248", "pmid": "23476897", "variant": "CYP2D6*5", "sentences": ["CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2."]}
{"pmcid": "PMC3584248", "pmid": "23476897", "variant": "CYP2D6*10", "sentences": ["CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2."]}
{"pmcid": "PMC3584248", "pmid": "23476897", "variant": "CYP2D6*41", "sentences": ["CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are associated with decreased concentrations of endoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2.", "CYP2D6 *10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10 are not associated with decreased concentrations of 4-hydroxytamoxifen, n-desmethyltamoxifen and tamoxifen in women with Breast Neoplasms as compared to CYP2D6 *1/*1 + *1/*2 + *2/*2."]}
{"pmcid": "PMC12035587", "pmid": "40099566", "variant": "NUDT15*3", "sentences": ["NUDT15 *3/*3 is associated with increased severity of Myelosuppression, Toxic liver disease and Alopecia when treated with mercaptopurine in women with Leukemia, Promyelocytic, Acute."]}
{"pmcid": "PMC10993165", "pmid": "38568509", "variant": "HLA-B*15:02", "sentences": ["HLA-B *15:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim."]}
{"pmcid": "PMC10993165", "pmid": "38568509", "variant": "HLA-B*13:01", "sentences": ["HLA-B *13:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim."]}
{"pmcid": "PMC10993165", "pmid": "38568509", "variant": "HLA-B*38:02", "sentences": ["HLA-B *38:02 is associated with increased likelihood of Stevens-Johnson Syndrome, Epidermal Necrolysis, Toxic or severe cutaneous adverse reactions when treated with sulfamethoxazole or sulfamethoxazole / trimethoprim."]}
{"pmcid": "PMC10399933", "pmid": "37490620", "variant": "CYP2C9*1", "sentences": ["CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) ."]}
{"pmcid": "PMC10399933", "pmid": "37490620", "variant": "CYP2C9*2", "sentences": ["CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) ."]}
{"pmcid": "PMC10399933", "pmid": "37490620", "variant": "CYP2C9*3", "sentences": ["CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) ."]}
{"pmcid": "PMC10399933", "pmid": "37490620", "variant": "rs4149056", "sentences": ["Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.", "Genotype CC is associated with increased risk of discontinuation when treated with simvastatin as compared to genotype TT.", "Genotypes CC + CT is associated with increased risk of discontinuation when treated with pravastatin as compared to genotype TT."]}
{"pmcid": "PMC10399933", "pmid": "37490620", "variant": "rs2231142", "sentences": ["Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG."]}
{"pmcid": "PMC4706412", "pmid": "26745506", "variant": "CYP4F2*1", "sentences": ["CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1."]}
{"pmcid": "PMC4706412", "pmid": "26745506", "variant": "CYP4F2*3", "sentences": ["CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1."]}
{"pmcid": "PMC4706412", "pmid": "26745506", "variant": "CYP2C9*1", "sentences": ["CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1."]}
{"pmcid": "PMC4706412", "pmid": "26745506", "variant": "CYP2C9*2", "sentences": ["CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1."]}
{"pmcid": "PMC4706412", "pmid": "26745506", "variant": "CYP2C9*3", "sentences": ["CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1."]}
{"pmcid": "PMC4706412", "pmid": "26745506", "variant": "CYP2C9*8", "sentences": ["CYP2C9 *2 + *3 + *8 are associated with decreased dose of warfarin as compared to CYP2C9 *1."]}
{"pmcid": "PMC4706412", "pmid": "26745506", "variant": "rs9923231", "sentences": ["Genotypes CT + TT are associated with decreased dose of warfarin as compared to genotype CC."]}
{"pmcid": "PMC4706412", "pmid": "26745506", "variant": "rs1800566", "sentences": ["Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG."]}
{"pmcid": "PMC6714829", "pmid": "30336686", "variant": "rs4149056", "sentences": ["Genotype TT is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotypes CC + CT."]}
{"pmcid": "PMC6714829", "pmid": "30336686", "variant": "rs2306283", "sentences": ["Genotypes AG + GG are not associated with increased response to simvastatin in people with Hypercholesterolemia as compared to genotype AA."]}
{"pmcid": "PMC2859392", "pmid": "20338069", "variant": "rs3745274", "sentences": ["Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.", "Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT."]}
{"pmcid": "PMC11603346", "pmid": "39604537", "variant": "CYP2B6*1", "sentences": ["CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1."]}
{"pmcid": "PMC11603346", "pmid": "39604537", "variant": "CYP2B6*6", "sentences": ["CYP2B6 *1/*6 + *6/*6 is associated with decreased likelihood of Drug-induced liver injury when treated with nevirapine in people with HIV infectious disease as compared to CYP2B6 *1/*1.", "CYP2B6 *1/*6 + *6/*6 is associated with increased likelihood of Drug-induced liver injury when treated with efavirenz in people with HIV infectious disease as compared to CYP2B6 *1/*1."]}
{"pmcid": "PMC8973308", "pmid": "35431360", "variant": "rs116855232", "sentences": ["Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC."]}
{"pmcid": "PMC8973308", "pmid": "35431360", "variant": "rs1800460", "sentences": ["Genotype CT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC."]}
{"pmcid": "PMC8973308", "pmid": "35431360", "variant": "rs1800462", "sentences": ["Genotype CG is associated with decreased likelihood of febrile neutropenia and discontinuation when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC."]}
{"pmcid": "PMC3387531", "pmid": "21505298", "variant": "HLA-B*35:01", "sentences": ["HLA-B *35:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC3387531", "pmid": "21505298", "variant": "HLA-DRB1*01:01", "sentences": ["HLA-DRB1 *01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC3387531", "pmid": "21505298", "variant": "HLA-C*04:01", "sentences": ["HLA-C *04:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC3387531", "pmid": "21505298", "variant": "rs3745274", "sentences": ["Allele T is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC3387531", "pmid": "21505298", "variant": "rs2054675", "sentences": ["Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections."]}
{"pmcid": "PMC3387531", "pmid": "21505298", "variant": "rs3786547", "sentences": ["Allele C is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV Infections."]}
